This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Health Stocks in Motion

Updated from 2:39 p.m. EDT

Shares of aaiPharma (AAII) were among the best-performing health and pharmaceutical stocks Monday, rising 34.1% after the company announced that it made a belated interest payment that was due Oct. 1, and it restructured its debt.

Late Friday, the drug company said that it received the requisite consents to adopt amendments required for its senior credit facility. As part of the restructuring, the senior debt amendment increased the amount of term loans available to aaiPharma by up to $30 million. The company tapped $20 million of these new loans to make a $10 million interest payment that was due Oct. 1. The remaining portion, the company said, is being used for working-capital purposes. Shares traded up 99 cents to $3.89.

Nastech Pharmaceutical (NSTK) rose 1.4% after the company received an approvable letter from the Food and Drug Administration for its nasal spray that's used for the treatment of vitamin B-12 deficiency. Before final product approval, the FDA must inspect Nastech's B-12 raw material manufacturing facility and finalization of the labeling must be completed. There were no other FDA requirements that would prevent the company from receiving final approval. Shares traded up 18 cents to $13.33.

Shares of AVI BioPharma (AVII) rose 4% after the company reported positive results from experiments testing the effect of its antisense drugs against the Ebola virus in vivo. The testing, which was conducted in collaboration with AVI, the U.S. Army Medical Research Institute of Infectious Diseases, and labs in Germany, showed that AVI's Neugene antisense drugs "may be a viable component of the country's biodefense strategy," the company said. The results were strong enough to convince the Army Medical Research Institute of Infectious Diseases to expand the research program. Shares traded up 9 cents to $2.34.
1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
ASTM $3.10 -0.18%
STEM $0.54 4.00%
AAPL $118.03 -0.71%
FB $105.41 -0.31%
GOOG $748.82 0.07%


Chart of I:DJI
DOW 17,813.39 +1.20 0.01%
S&P 500 2,088.87 -0.27 -0.01%
NASDAQ 5,116.1430 +13.3350 0.26%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs